Cayman Alw-Ii-41-27; Purity- Greater Than Or Equal To 95%; Size-

ALW-II-41-27 is a multi-kinase inhibitor that inhibits EphB2, EphA3, Kit, FMS, VEGFR2/KDR, FLT1, FGR, Src, Lyn, BMX, and Bcr-Abl in tyrosine kinase-transformed Ba/F3 cells (EC₅₀s = <500 nM).¹ ALW-II-41-27 also inhibits DDR2 and Src (IC₅₀s = 51 and 14 nM, respectively) as well as wild-type and mutant RET kinases (IC₅₀s = 24.7, 94.2, and 15.8 nM for wild-type, RET^V804L, and RET^V804M, respectively).^2,3 It reduces growth of NCI-H2286 and HCC-366 cancer cells (GI₅₀s = 0.51 and 0.65 μM, respectively) and RAT1 cells transformed by RET^C634R or RET^M918T (IC₅₀s = 44 and 56 nM, respectively). ALW-II-41-27 also inhibits growth of MDA-MB-231 breast cancer cells in a concentration-dependent manner and inhibits tumor growth in vivo in a mouse patient-derived xenograft (PDX) model of EphA2-overexpressing triple-negative breast cancer (TNBC).⁴

WARNING This product is not for human or veterinary use.